Evidence map›Paper›PMID 21300829›Full record

ArticleAntimicrobial agents and chemotherapy2011

Benzimidazole analogs inhibit human herpesvirus 6.

Mark N Prichard, Samuel L Frederick, Shannon Daily, Katherine Z Borysko, Leroy B Townsend, John C Drach, Earl R Kern

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Anti-CMV therapy, what next? A systematic review.Frontiers in microbiology · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mark N PrichardUniversity of Alabama School of Medicine, 1600 6th Avenue South, 128 Children's Harbor Building, Birmingham, AL 35233, USA. mprichard@peds.uab.edu
Samuel L Frederick
Shannon Daily
Katherine Z Borysko
Leroy B Townsend
John C Drach
Earl R Kern

Funding

NIAID NIH HHS HHSN272201100001CNIAID NIH HHS HHSN272201100001GNIAID NIH HHS HHSN272201100010CNIAID NIH HHS N01 AI030049NIAID NIH HHS N01-AI-30049PHS HHS HHSN2722011000010C
6 · The paper itself

Abstract

Several benzimidazole nucleoside analogs, including 1H-β-D-ribofuranosyl-2-bromo-5,6-dichlorobenzimidazole (BDCRB) and 1H-β-L-ribofuranosyl-2-isopropylamino-5,6-dichlorobenzimidazole (maribavir [MBV]), inhibit the replication of human cytomegalovirus. Neither analog inhibited the related betaherpesvirus human herpesvirus 6 (HHV-6). Additional analogs of these compounds were evaluated against both variants of HHV-6, and two L-analogs of BDCRB had good antiviral activity against HHV-6A, as well as more modest inhibition of HHV-6B replication.

Indexed as

Antiviral AgentsBenzimidazolesCytomegalovirusHerpesvirus 6, HumanHumansVirus ReplicationAntiviral AgentsBenzimidazoles

Identifiers

PMID21300829
PMCPMC3088228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.